First Time Loading...

Yield10 Bioscience Inc
NASDAQ:YTEN

Watchlist Manager
Yield10 Bioscience Inc Logo
Yield10 Bioscience Inc
NASDAQ:YTEN
Watchlist
Price: 0.2727 USD -2.61%
Updated: Apr 19, 2024
Section:
 

Relative Value

YTEN doesn't have a meaningful market cap.

The Relative Value of one YTEN stock under the Base Case scenario is 14.8732 USD. Compared to the current market price of 0.2727 USD, Yield10 Bioscience Inc is Undervalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

YTEN Relative Value
Base Case
14.8732 USD
Undervaluation 98%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

70
P/S
P/S
Price to Sales
70
vs History
82
vs Industry
18
Median 3Y
40.2
Median 5Y
28.6
Industry
8.1
Forward
1.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.1
Industry
26.2
Forward
-0.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.3
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.3
Industry
21.4
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
7
Median 3Y
1.8
Median 5Y
1.7
Industry
2.6
More Details
52.2
EV/S
EV/S
Enterprise Value to Sales
52.2
vs History
82
vs Industry
17
Median 3Y
17.4
Median 5Y
11.7
Industry
7.4
Forward
1.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
29
Median 3Y
-0.6
Median 5Y
-0.5
Industry
5.1
Forward
-0.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
27
Median 3Y
-0.5
Median 5Y
-0.5
Industry
4.8
Forward
-0.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
30
Median 3Y
-0.7
Median 5Y
-0.6
Industry
6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
26
Median 3Y
-0.7
Median 5Y
-0.6
Industry
3.7
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
87
vs Industry
49
Median 3Y
1.9
Median 5Y
1.1
Industry
5
More Details

Multiples Across Competitors

YTEN Competitors Multiples
Yield10 Bioscience Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Yield10 Bioscience Inc
NASDAQ:YTEN
4.2m USD 70 -0.3 -0.2 -0.2
US
Abbvie Inc
NYSE:ABBV
292.2B USD 5.4 60.5 13.1 20
US
Amgen Inc
NASDAQ:AMGN
142B USD 5 21.1 15.9 23.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102B USD 10.3 28.2 22.5 23.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
98.2B USD 7.5 24.8 16.4 18.1
AU
CSL Ltd
ASX:CSL
130.2B AUD 5.9 33.8 20.6 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
82.9B USD 3.1 14.6 8.9 11.8
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
39.4B USD 5.7 -8.3 -8.7 -7.4
US
Biogen Inc
NASDAQ:BIIB
27.7B USD 2.8 23.9 13.1 16.3
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47
EV/EBITDA Multiple
EBITDA Growth
US
Yield10 Bioscience Inc
NASDAQ:YTEN
Average EV/EBITDA: 17.3
Negative Multiple: -0.2 		N/A
US
Abbvie Inc
NYSE:ABBV
13.1
25%
US
Amgen Inc
NASDAQ:AMGN
15.9
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
51%
AU
CSL Ltd
ASX:CSL
20.6
54%
US
Gilead Sciences Inc
NASDAQ:GILD
8.9
29%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.7 N/A
US
Biogen Inc
NASDAQ:BIIB
13.1
71%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
27.9
83%

See Also

Summary
YTEN intrinsic value, competitors valuation, and company profile.
DCF Valuation
YTEN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YTEN stock valuation using valuation multiples.
Wall Street Estimates
YTEN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YTEN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 129,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.